Publicaciones en las que colabora con Miguel Fernández de Sanmamed Gutiérrez (18)

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  3. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

    Theranostics, Vol. 12, Núm. 3, pp. 1373-1387

2021

  1. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  2. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

  3. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

    European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280

  4. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8

    Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201

  5. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393

  6. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death

    Theranostics, Vol. 10, Núm. 10, pp. 4481-4489

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

  3. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

2015

  1. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2013

  1. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162

  2. Interleukin-15 in gene therapy of cancer

    Current Gene Therapy, Vol. 13, Núm. 1, pp. 15-30

2012

  1. The liver, liver metastasis and liver cancer: A special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies

    Immunotherapy, Vol. 4, Núm. 11, pp. 1081-1085